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Abstract : We investigated the usefulness of the urinary myoinositol index 
（UMI） for identifying postmeal hyperglycemia in type 2 diabetics undergoing a 
meal tolerance test.  Fifty-eight patients （18 males, 40 females） were enrolled, 
fasted overnight and blood collected prior to and 1 and 2 hours following 
the test meal.  Urine was collected 2 hours after the test meal.  Plasma 
1,5-anhydroglucitol （1,5-AG） was measured enzymatically, and UMI with an 
improved enzymatic cycling method.  Simple and multiple regression analyses 
were employed to determine correlations between plasma glucose （PG） and 
three PG markers ; HbA1C （Japan Diabetes Society）, 1,5-AG and UMI.  Study 
population characteristics were age 67.6±7.9 years, body mass index 24.9±
3.8 kg / m2 and waist circumference 90.2±10.4 cm.  Mean concentrations for 
PG were 130±23 mg / dL （fasting）, 179±46 mg / dL （1 h postmeal） and 150
±49 mg / dL （2 h postmeal）, HbA1C （6.3±0.6％）, 1,5-AG （11.9±5.7μg / mL） 
and 2 h UMI （52.0±35.9 mg / gCr）.  Correlation coefficients were calculated 
between 1 h postmeal PG and HbA1C （r＝0.558）, 1,5-AG （r＝0.256）, and 
2 h UMI （r＝0.496）, and 2 h postmeal PG HbA1C （r＝0.605）, 1,5-AG （r＝
0.306）, and 2 h UMI （r＝0.606）.  Two hour UMI and HbA1C （Japan Diabetes 
Society） were signicant determinants of 2 h postmeal PG.  As HbA1C reects 
PG excursion during the previous 1-3 months, UMI may be a useful marker 
for monitoring and management of postmeal hyperglycemia in type 2 diabetics.
Key words : postmeal hyperglycemia, glucose excursion, urinary myoinositol 
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Introduction
　A growing body of evidence suggests that reducing postmeal （postprandial） plasma 
glucose （PG） excursions as well as achieving hemoglobin A1C （HbA1C） goals is important 
for the prevention of cardiovascular disease （CVD）1-4）.  There are many markers used to 
monitor PG control and diabetes management, e.g. HbA1C, glycoalbumin （GA）, fructosamine, 
1,5-anhydroglucitol （1,5-AG）.  Plasma 1,5-AG is a naturally occurring dietary polyol that has 
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also been proposed as a marker for postmeal hyperglycemia5, 6）.
　Myoinositol is one form of inositol, a circular D-glucose isomer, which is stable in urine 
samples at room temperature7, 8）.  Plasma myoinositol concentration is stable and remains 
within physiological concentration even in patients with abnormal glucose tolerance.  How-
ever, urinary myoinositol concentration increases during hyperglycemia9, 10）.  Thus, urinary 
myoinositol concentration may be a useful new indicator of PG excursions.  The Urinary 
Myoinositol Index （UMI）, calculated as the ratio of urinary myoinositol to creatinine, has 
also been reported to be a new and appropriate marker for abnormal glucose tolerance, and 
is now covered by health insurance in Japan.
　However, the relationship between UMI and postmeal PG excursion has not been fully 
clarified.  Therefore, we examined the relationship between postmeal hyperglycemia and 
HbA1C, plasma 1,5-AG or UMI in patients with type 2 diabetes mellitus （T2DM） undergo-
ing a meal tolerance test.
Material and Methods
　Fifty-eight T2DM patients （18 males and 40 females） were enrolled consecutively in this 
study.  Patients with renal disease （plasma creatinine ≥1.2 mg / dL ; 110μmol / L or protein-
uria ≥2＋）, hepatic disease, those using insulin or α-glucosidase inhibitors （α-GI）, and those 
with HbA1C above 8.0％ were excluded from this study.  All study protocols and procedures 
were approved by the Ethics Committee of Toho University Medical Center Omori Hospi-
tal.  The study objectives and intended procedures were individually explained to all study 
participants, and all completed the study.  Written informed consent was obtained from all 
participants.  This was a prospective study, and its term was between October 2007 and 
June 2008.
　Test meal A was fed to all participants and was composed of cream of chicken soup, 6 
crackers, and pudding.  This food contained 51.4％ carbohydrate （57.6 g）, 15.3％ protein and 
33.3％ lipid and had a total energy content of 460 kcal.
　A venous blood sample was collected after an overnight fast of at least 10 hours.  There-
after, patients passed urine, and the meal tolerance test was performed.  All subjects con-
sumed test meal A within 15 minutes along with 100 ml of water, and blood samples were 
collected 1 and 2 hours postprandially.  Urine samples were collected 2 hours postprandially 
（Table 1）.
　Fasting and postmeal PG and HbA1C were measured by AutoAnalyzer.  Plasma 1,5-AG 
was measured using a fully enzymatic method11）, and urinary myoinositol by an improved 
enzymatic cycling method12）.  The UMI was calculated as the ratio of urinary myoinositol 
to creatinine.  The HbA1C concentrations were expressed using values standardized by the 
Japan Diabetes Society （JDS）.
　All values are expressed as mean±SD.  Simple and multiple regression analyses were 
employed to determine correlations between PG and PG markers （HbA1C, 1,5-AG and 2 
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h UMI）.  All statistical analysis was performed employing Excel 2007-Microsoft OfficeⓇ 
software package.  A signicant difference was dened as P＜0.05.
Results
　Patient characteristics were age （67.6±7.9 years）, body mass index （BMI） （24.9±3.8 kg /
m2） and waist circumference （90.2±10.4 cm）.  HbA1C （JDS）, 1,5-AG and 2 h UMI were 6.3
±0.6％, 11.9±5.7μg / mL and 52.0±35.9 mg / gCr, respectively （Table 2）.  Plasma glucose 
concentrations were 129.9±22.9 mg / dL （fasting）, 178.5±45.9 mg / dL （1 h） and 149.9±48.7 
mg / dL （2 h） （Fig. 1）.  Figure 2 shows the relationship between HbA1C （JDS） and 0 h 
PG, 1 h PG or 2 h PG.  The highest correlation coefcient was between HbA1C （JDS） and 
2 h PG （r＝0.605）.  The relationship between 1,5-AG and 0 h, 1 h or 2 h PG is shown in 
Fig. 3, with the highest correlation found between 1,5-AG and 2 h PG （r＝0.306）.  Figure 
4 shows the relationship between 2 h UMI and 0 h, 1 h and 2 h PG.  The highest correla-
tion coefcient was for the relationship between 2 h UMI and 2 h PG （r＝0.606）.  For 
all markers, the highest correlation coefficient was for the relationship between PG and 
PG markers at 2 h postprandially.  Of the three PG markers, 2 h UMI and HbA1C （JDS） 
showed the highest correlation coefcients for the relationship with postmeal PG.
　The relationship between area under the glucose curve ［AUC（PG）］ measured at the 
three time points （0, 1 and 2 h postmeal） and the three PG markers is summarized in 
Table 3.  All three PG markers were associated with AUC（PG）.  To identify markers that 
are associated with 2 h PG, we performed a multiple regression analysis between 2 h PG 
and the three PG markers.  An association was found between 2 h PG and HbA1C （JDS） 
Table 1.　Blood and urine sampling points
fasting postmeal
0-h 1-h 2-h
PG ⊗ ⊗ ⊗
HbA1C （JDS） ⊗ - -
1,5-AG ⊗ - -
2-h UMI - - ⊗
HbA1C （JDS）: hemoglobin A1C （Japan Diabe-
tes Society）, 1,5-AG : 1,5-anhydroglucitol, 2-h 
UMI : 2-hour urinary myoinositol index.
Table 2.　Baseline characteristics of study subjects
Gender （male / female） 18 / 40
Age （years） 67.6 ±7.9
BW （kg） 64.5 ±10.7
BMI （kg / m2） 24.9 ±3.8
Waist circumference （cm） 90.2 ±10.4
Duration of diabetes （years） 7.5 ±4.4
HbA1C （JDS） （％） 6.3 ±0.6
1,5-AG （μg / mL） 11.9 ±5.7
2-h UMI （mg / gCr） 52.0 ±35.9
Treatment for diabetes
diet / exercise 9（16％）
monotherapy 13（22％）
combination therapy 36（62％）
All values are expressed as mean±SD or number.
BW : body weight, BMI : body-mass index, HbA1C 
（JDS）: hemoglobin A1C （Japan Diabetes Society）, 
1,5-AG : 1,5-anhydroglucitol, 2-h UMI : 2-hour 
urinary myoinositol index.
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Fig. 1.　Plasma glucose changes during test meal loading
Open diamonds indicate plasma glucose concentration. Vertical bars indicate mean±SD.
PG : plasma glucose, 0-h : 0-hour, 1-h : 1-hour, 2-h : 2-hour.
Fig. 2.　Simple linear correlation between PG and HbA1C （JDS）
Scatter diagram of association between PG and HbA1C （JDS） with open circles indicating 
analyte values and showing an approximately linear relationship. Left, middle and right 
panels indicate the relationship between PG and HbA1C at 0-hour, 1-hour, and 2-hour, 
respectively.
PG : plasma glucose, HbA1C （JDS）: hemoglobin A1C （Japan Diabetes Society）, 0-h : 0-hour, 
1-h : 1-hour, 2-h : 2-hour.
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Fig. 3.　Simple linear correlation between PG and 1,5-AG
Scatter diagram of association between PG and 1,5-AG with open triangles indicating ana-
lyte values and showing an approximately linear relationship. Left, middle and right panel 
indicate the relationship between PG and 1,5-AG, at 0-hour, 1-hour, and 2-hour, respectively.
PG : plasma glucose, 1,5-AG : 1,5-anhydroglucitol, 0-h : 0-hour, 1-h : 1-hour, 2-h : 2-hour.
Fig. 4.　Simple linear correlation between PG and 2-h UMI
Scatter diagram of association between PG and 2-h UMI with open squares indicating 
analyte values and showing an approximately linear relationship. Left, middle and right 
panel indicate the relationship between PG and 2-h UMI, at 0-hour, 1-hour, and 2-hour, 
respectively.
PG : plasma glucose, 2-h UMI : 2-hour urinary myoinositol index, 0-h : 0-hour, 1-h : 1-hour, 
2-h : 2-hour.
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or 2 h UMI （Table 4）.
Discussion
　Patients with type 2 diabetes mellitus are at increased risk for atherosclerotic diseases such 
as coronary heart disease and stroke.  Many long-term studies and meta-analyses have been 
published on the clinical signicance of postmeal or post-glucose loaded hyperglycemia for 
macroangiopathy and mortality.  The Funagata Study reported that the cumulative survival 
rates from CVD events associated with impaired glucose tolerance （IGT）, were similar 
to those of diabetes, however that of impaired fasting glucose （IFG） was not signicantly 
lower than that of normal fasting glucose 13）.  Further, the Diabetes Epidemiology Collabora-
tive analysis Of Diagnostic criteria in Europe Study （DECODE Study） reported that the 
2 h postprandial blood glucose following the 75 g oral glucose tolerance test （75 g OGTT） 
was a better predictor of deaths from all causes and CVD than fasting blood glucose14）. 
Moreover, The Diabetes Intervention Study （DIS）, a prospective population-based multicen-
tre trial of newly detected cases of non-insulin-dependent diabetes mellitus, used multivariate 
analysis to show that postmeal blood glucose is an independent risk factor for myocardial 
infarction15）.  Thus, postmeal hyperglycemia is now known to be an important risk factor for 
CVD, even in non-diabetic subjects and patients with IGT 3, 4, 13）.
　Therefore, identifying the best marker for postmeal blood glucose excursion has become 
important.  Currently, there are many clinical markers used to monitor and manage PG 
and treat diabetes ; with urinary myoinositol concentration proposed as a useful marker of 
postmeal hyperglycemia.
　Inositol is a naturally occurring nutrient that is usually classied as a carbocyclic polyol. 
Myoinositol, one form of inositol, is an extremely stable circular alcohol and is supplied 
daily from the diet and by renal biosynthesis7, 8）.  Myoinositol in the plasma of healthy 
individuals is maintained at physiological concentration （approximately 25μmol / L）, but its 
Table 3. Correlation coefficients between AUC
（PG） （0-2h） and HbA1C （JDS）, 1,5-AG 
or 2-h UMI
PG markers r P value
HbA1C （JDS） （％） 0.6405 ＜0.00001
1,5-AG （μg / ml） 0.2985 0.02283
2-h UMI （mg / gCr） 0.5625 ＜0.00001
P values indicate the association between AUC
（PG） （0-2h） and three PG markers.
AUC : area under the curve, PG : plasma glucose, 
r : correlation coefficient, HbA1C （JDS）: hemo-
globin A1C （the Japan Diabetes Society）, 1,5-
AG : 1,5-anhydroglucitol, 2-h UMI : 2-hour urinary 
myoinositol index.
Table 4.　Multiple regression analysis to determine 
factors that influence the value of 2-h 
PG
Factors P value
HbA1C （JDS） （％） 0.00853
1,5-AG （μg / ml） 0.88366
2-h UMI （mg / gCr） 0.00942
P values indicate the association between between 
2-h PG and three PG markers.
PG : plasma glucose, HbA1C （JDS）: hemoglobin 
A1C （the Japan Diabetes Society）, 1,5-AG : 1,5- 
anhydroglucitol, 2-h UMI : 2-hour urinary myoino-
sitol index.
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concentration in urine is reported to be higher in patients with diabetes or chronic renal 
failure16-19）.  Myoinositol is transported in renal tubules and excreted in urine, as is 1,5-AG. 
The reabsorption of myoinositol is competitively inhibited by the urinary glucosuria induced 
by hyperglycemia.
　We used a highly sensitive method to measure urinary myoinositol.  The measurable 
range for myoinositol using this method extends from 10 to 1,500μmol / L.  Urinary 
myoinositol / creatinine ratio was calculated following a meal load.  A previous study which 
performed a 75 g OGTT and monitored UMI for the subsequent 3 hours in patients with 
normal glucose tolerance （NGT）, IGT and diabetes, found peak values at 2 hours postpran-
dially.  Moreover, the UMI value was higher with greater degrees of glucose intolerance 20）. 
The mean UMI at 2 h following test meal loading for subjects with NGT was 18.0±10.6 
mg / gCr, and the estimated normal range was from 7.4 to 28.6 mg / gCr.
　In this study, 1 h PG was greater than 2 h, but the three PG markers studied were more 
closely associated with 2 h than 1 h PG.  Further, the correlation coefficient relating 2 h 
PG and 2 h UMI was greater than that between 2 h PG and 1,5-AG or HbA1C （JDS）. 
Multiple regression analysis revealed that 2 h UMI as well as HbA1C （JDS） were signicant 
determinants of 2 h PG.
　Currently, HbA1C, GA, 1,5-AG and PG are mainstream markers used to indicate glycemic 
control in diabetics.  The benet of HbA1C, GA and 1,5-AG measured in blood and plasma 
samples is that they are unaffected by increases in PG following a single meal load.  Of 
these PG markers, 1,5-AG has been proposed as a marker for postmeal hyperglycemia.  It 
accurately reflects recent PG increases （within a few days,） and its daily recovery rate 
is constant （0.3μg / mL / day） in and between those individuals with excellent glycemic 
control 21）.  Dungan et al evaluated the relationship between postprandial hyperglycemia 
and glycemic markers using a continuous glucose monitoring system.  They concluded that 
1,5-AG reflected glycemic excursions, often in the postprandial state, more robustly than 
fructosamine or HbA1C22）.  A similar study was carried out by Suwa et al 23）.  They showed 
that GA, compared with HbA1C and 1,5-AG, reflected not only short-term mean blood 
glucose concentration but also glycemic uctuation.  To our knowledge, there is no report 
denitively identifying the best marker for postmeal hyperglycemia.  However, in the current 
study the correlation coefficient between postmeal PG and 1,5-AG was lower than that 
between postmeal PG and 2 h UMI.  Thus, 2 h UMI may be a better marker for postmeal 
hyperglycemia than 1,5-AG.
　In our study, HbA1C was also a good marker for 1 h or 2 h postprandial PG as indicated 
by the correlation between AUC（PG） and HbA1C （Table 3）, and the results of the 
multiple regression analysis （Table 4）.  However, it neither accurately reects transient eleva-
tions of PG occurring within a few days, nor responds quickly to changes in PG （including 
fasting and postmeal）.  Furthermore, anemic subjects often demonstrate lower HbA1C values 
because of a rapid turnover of red blood cells.  The values for 1,5-AG and 2 h UMI may, 
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therefore, be better for monitoring postmeal hyperglycemia than HbA1C.
　The advantages of UMI include non-invasive sample collection, and a rapid change in 
value in response to changes in PG.  Thus, compared to HbA1C and 1,5-AG, the measure-
ment of 2 h UMI is easier because blood sampling is not necessary, however the test has 
several limitations.  First, urine sampling at exactly 2 h postprandially was required ; second, 
similar to 1,5-AG, pseudo-positive reactions were found in patients with renal glycosuria 20）; 
third, it is currently unknown what drugs may inuence the UMI value.
Conclusion
　UMI seems to be a better marker for monitoring postmeal hyperglycemia compared with 
plasma 1,5-AG or HbA1C, and so it may help monitor and manage postmeal （postprandial） 
PG in diabetic subjects.
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